Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Echocardiography; Procedure: Radionuclide Imaging; Drug: Vismodegib Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Conditions: Gastroesophageal Cancer Interventions: Biological: MK-2870; Drug: Trifluridine-Tipiracil; Drug: Irinotecan; Drug: Paclitaxel; Drug: Docetaxel Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer (NSCLC) Interventions: Drug: Tislelizumab; Drug: Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC); Drug: Carboplatin or Cisplatin; Procedure: Surgery Sponsors: The Affiliated Hospital of Qingdao University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Conditions: Cervical Cancer; Anal Cancer; Head and Neck Cancers; Other Solid Tumors Interventions: Drug: CRTE7A2-01 TCR-T cell therapy Sponsors: Corregene Biotechnology Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
Conditions: Metastatic Colon Cancer; Metastatic Rectum Cancer Interventions: Drug: Topical Tretinoin; Other: Placebo Sponsors: University of Utah Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Linking Somatic Mutation Rate With Baseline Exposure in East Palestine
Conditions: Somatic Mutation Interventions: Other: Survey; Other: Biological specimen collection; Other: Communications about study updates and future research opportunities; Other: Qualitative interview Sponsors: Case Comprehensive Cancer Center; National Institutes of Health (NIH); National Institute of Environmental Health Sciences (NIEHS) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population
Conditions: Breast Cancer Sponsors: Ain Shams University; British University In Egypt Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Sacituzumab Govitecan Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Australasian Malignant PLeural Effusion (AMPLE)-4 trial: study protocol for a multi-centre randomised trial of topical antibiotics prophylaxis for infections of indwelling pleural catheters
DiscussionResults from this trial will determine the efficacy of mupirocin prophylaxis in patients who require IPC for MPE. It will provide data on infection rates, microbiology, and potentially infection pathways associated with IPC-related infections.Ethics and disseminationSir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics Committee has approved the study (RGS0000005920). Results will be published in peer-reviewed journals and presented at scientific conferences.Trial registrationAustralia New Zealand Clinical Trial Registry ACTRN12623000253606. Registered on 9 March 2023. (Source: Trials)
Source: Trials - April 10, 2024 Category: Research Source Type: clinical trials
Real World Prostate Cancer Registry
Conditions: Prostate Cancer Sponsors: Cincinnati Cancer Advisors Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA Gene Overexpression
CAMBRIDGE, Mass.--(BUSINESS WIRE) April 09, 2024 -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 9, 2024 Category: Pharmaceuticals Source Type: clinical trials
Practical Ultrasonographic Detection of Sarcopenia in Patients With Long-term Gastrectomy
Conditions: Sarcopenia; Gastrectomy Interventions: Diagnostic Test: USG, Grip strength, Chair stand test (CST) Sponsors: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Conditions: Renal Insufficiency; Upper Urinary Tract Urothelial Carcinoma; Solitary Kidney Interventions: Drug: DV; Drug: Toripalimab; Procedure: Laser surgery Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Conditions: Hepatocellular Carcinoma Interventions: Drug: Alectinib (Alecensa), Nivolumab (Opdivo) Sponsors: China Medical University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Hepatocellular Carcinoma Liver Organoids
Conditions: Hepatocellular Carcinoma Interventions: Procedure: Liver biopsy Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
